Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received a consensus recommendation of "Hold" from the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $7.30.

Several equities research analysts have commented on the company. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price on the stock. HC Wainwright restated a "buy" rating on shares of Esperion Therapeutics in a report on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price objective for the company. Finally, StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ESPR. Public Employees Retirement System of Ohio acquired a new position in Esperion Therapeutics during the third quarter worth approximately $606,000. Anson Funds Management LP acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth approximately $540,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock valued at $1,174,000 after acquiring an additional 295,378 shares during the period. Wellington Management Group LLP lifted its holdings in Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company's stock valued at $995,000 after purchasing an additional 241,512 shares during the last quarter. Finally, Wasatch Advisors LP boosted its position in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Trading Up 7.8 %

Shares of ESPR stock traded up $0.17 during trading hours on Friday, hitting $2.34. 5,182,020 shares of the company were exchanged, compared to its average volume of 4,372,332. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The business has a 50 day moving average of $2.46 and a two-hundred day moving average of $2.18. The company has a market capitalization of $461.06 million, a PE ratio of -3.66 and a beta of 1.03.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.